Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in... Contact Us. Contact Us.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the ...

The Cedilla pipeline lists the program between preclinical and IND. The upshot is Bayer has ceded a head start to its rivals for the CDK2 market. Pfizer is set to present phase 1/2a data on its ...

“Cedilla is proud to partner with Bayer on this exciting programme,” said Neil Exter, chief executive officer of Cedilla Therapeutics and Partner at Third Rock Ventures. “Cedilla's bespoke molecules ...

Bayer AG and Cedilla Therapeutics Inc. have entered into an exclusive license agreement to develop and commercialize Cedilla Therapeutics' cyclinE1/cyclin dependent kinase 2 (CDK2) complex inhibitors, ...